-+ 0.00%
-+ 0.00%
-+ 0.00%

Zealand Pharma says Phase 2 ZUPREME-1 trial shows petrelintide cuts weight up to 10.7% at 42 weeks

PUBT·09/29/2026 22:03:31
Listen to the news
Zealand Pharma says Phase 2 ZUPREME-1 trial shows petrelintide cuts weight up to 10.7% at 42 weeks
  • Zealand Pharma flagged Phase 2 ZUPREME-1 results for petrelintide in obesity, now published, with additional data due at EASD 2026.
  • Findings showed clinically meaningful weight loss with gastrointestinal tolerability broadly comparable to placebo, supporting patient persistence potential.
  • Study also indicated improvements in cardiometabolic risk markers, strengthening the drug’s profile beyond weight reduction.
  • Additional results will be presented on September 30, 2026 at 3:30 p.m. CEST in an EASD oral session.
  • A global Phase 3 registrational program for petrelintide monotherapy in chronic weight management has been initiated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291803PRIMZONEFULLFEED1001275299) on September 29, 2026, and is solely responsible for the information contained therein.